Clinical trials: Empagliflozin
Heart Failure
Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale
This study aims at exploring the use of Dapagliflozin and Empagliflozin in children and adolescents 6-18 years old with heart failure.
- Trial name
- NCT06012266
- Testing
- Dapagliflozin tablet, Empagliflozin Tablets
- Where
- 3 sites in Switzerland, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Type 2 Diabetes
SGLT2i, Pioglitazone, and Ketone Production in T2D
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
- Trial name
- NCT07053319
- Testing
- Empagliflozin 25 MG, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions in Chinese Healthy Volunteers.
- Trial name
- NCT03771781
- Testing
- Empagliflozin Tablets, Empagliflozin Tab 25 MG
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Pharmacokinetics
The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin
An Open-label, One way, Two period Comparative study To Determine The effect of Morning Versus Evening administration of Empagliflozin 10mg on Its Pharmacokinetics And Pharmacodynamics in Healthy Adults
- Conditions
- Diabetes Mellitus, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT03895229
- Testing
- Empagliflozin 10 MG Oral Tablet [Jardiance]
- Where
- Egypt
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Healthy
Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets
The primary objective of this trial is to establish bioequivalence of two FDC tablets and the single tablets when administered together after a high fat high caloric meal.
- Trial name
- NCT01672788
- Testing
- Empagliflozin, Empagliflozin + Metformin, Metformin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes Mellitus
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
Single-center, prospective, active-controlled, open, randomized, 2 arm parallel, interventional, exploratory pilot Type 2 diabetic patients with high cardiovascular risks who have inadequate glycaemic control with metformin-based…
- Trial name
- NCT02964572
- Testing
- Glimepiride, Empagliflozin
- Where
- South Korea
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Type 2 Diabetes Mellitus
Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Madalena association in the treatment of type 2 diabetes mellitus.
- Trial name
- NCT04670666
- Testing
- MADALENA ASSOCIATION, METFORMIN, EMPAGLIFLOZIN + LINAGLIPTIN
- Where
- Brazil
- Volunteers
- 270 people
- Sponsor
- EMS
Perioperative Complication
SGLT2 Inhibitors and Perioperative Period
The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University.
- Trial name
- NCT06326528
- Testing
- SGLT2 inhibitor
- Volunteers
- 100 people
- Sponsor
- Assiut University
Healthy Volunteers
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
The purpose of this study is to compare the pharmacokinetics and safety of HDP023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
- Trial name
- NCT07102719
- Testing
- HD-P023, Teneligliptin and Empagliflozin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Kidney Transplant, Chronic Kidney Disease
Empagliflozin Treatment in Kidney Transplant Recipients
Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging.
- Trial name
- SEKTR (NCT06013865)
- Testing
- Empagliflozin
- Where
- 5 sites in United States
- Volunteers
- 264 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus Type 2 (T2DM)
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
SGLT2 inhibitors are a novel class of glucose lowering drugs that act in the kidney by inhibiting SGLT2-mediated glucose reabsorption in the proximal tubule.
- Trial name
- EMPA (NCT03132181)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- RWTH Aachen University
Aging, Arterial Stiffness
Empagliflozin Reversal of Arterial StiffnEss in Aging
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial…
- Trial name
- ERASE-Aging (NCT06506422)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Glycogen Storage Disease Type I, Glucose 6 Phosphatase Deficiency
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency
Treatment of neutropenia of G6PC3 and Glycogenosis type 1b patients with empagliflozin
- Trial name
- GLYCO-1B (NCT04138251)
- Testing
- Empagliflozin
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation.
- Trial name
- NCT03492580
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 714,582 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Hypertrophic Cardiomyopathy, Heart Failure
Empagliflozin in Hypertrophic Cardiomyopathy
The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study.
- Trial name
- EMPA-REPAIR (NCT05182658)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Poland
- Volunteers
- 250 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Diabetes Mellitus, Type 2
Regulatory Request NIS in Korea
To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting
- Trial name
- NCT03642717
- Testing
- JARDIANCE DUO®
- Where
- 20 sites in South Korea
- Volunteers
- 658 people
- Sponsor
- Boehringer Ingelheim
Cancer
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
Doxorubicin induced cardiomyopathy is the most common and serious side effect associated with doxorubicin treatment in cancer patients receiving doxorubicin.
- Trial name
- NCT06103279
- Testing
- Empagliflozin 10 MG
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Chronic Kidney Disease Requiring Hemodialysis
Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study
Patients with end-stage kidney disease (ESKD) on hemodialysis face an unacceptably high rate of cardiovascular complications, including heart failure, arrhythmias, and sudden cardiac death.
- Trial name
- SGLT2-HD (NCT06929169)
- Testing
- iSGLT2
- Where
- Argentina
- Volunteers
- 80 people
- Sponsor
- Maximo Agustin Schiavone
Diabetes Mellitus, Type 2
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
This is a non-interventional study using existing data including medical chart review.
- Trial name
- NCT03807440
- Testing
- Empagliflozin, Sodium Glucose Transporter 2 inhibitor, Dipeptidyl-peptidase 4 inhibitor
- Where
- 177 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 4,083 people
- Sponsor
- Boehringer Ingelheim